WASHINGTON - US biotech firm Novavax's COVID-19 vaccine was shown to be 100 percent protective against severe cases of the disease, including hospitalization and death, the company said last Thursday following trials.
In a Phase 3 trial in Britain that included 15,000 participants aged 18-84, including 27 percent over the age of 65, efficacy against mild, moderate and severe COVID was 96.4 percent against the original strain. Across both trials, the vaccine known as NVX-CoV2373 demonstrated 100 percent protection against severe disease.
May mas tiwala pa ko rito kesa sa sinovac
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação: